Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma

BACKGROUND: In the U.K. Medical Research Council Myeloma IX trial (mmix), zoledronic acid 4 mg once every 3–4 weeks, compared with clodronate 1600 mg daily, reduced the incidence of skeletal related events (sres), increased progression-free survival (pfs), and prolonged overall survival (os) in 1970...

詳細記述

保存先:
書誌詳細
主要な著者: Delea, T.E., El Ouagari, K., Rotter, J., Wang, A., Kaura, S., Morgan, G.J.
フォーマット: Artigo
言語:Inglês
出版事項: Multimed Inc. 2012
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3503670/
https://ncbi.nlm.nih.gov/pubmed/23300363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.19.1004
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料